Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,669 recruiting studies in this area right now.
By phase
- Not applicable9,830
- Phase 24,462
- Phase 12,741
- Phase 1/Phase 21,687
- Phase 31,405
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer659
- Prostate Cancer657
- Colorectal Cancer496
- Lung Cancer428
- Ovarian Cancer338
- Multiple Myeloma329
- Gastric Cancer300
- Pancreatic Cancer296
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer232
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University311
- Memorial Sloan Kettering Cancer Center289
- Sun Yat-sen University289
- National Cancer Institute (NCI)288
- Mayo Clinic238
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas641
- Arizona513
- Florida446
- Alabama420
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania241
Recruiting studies20,669 total
- NCT05460975Recruiting
Study of dense breast tissue seen on ultrasound
This study looks at breast cancer risk by analyzing what is seen in dense breast tissue during a screening ultrasound. It may help improve how doctors evaluate risk in people with very dense breasts.
SeoulAges 40–69 - NCT05465174RecruitingPhase 2
Tovorafenib for children and young adults with craniopharyngioma
This trial studies tovorafenib to treat craniopharyngioma in children and young adults. It aims to shrink the tumor or slow its growth, and to learn which patients benefit most and what side effects to expect.
Birmingham, AlabamaAges 1–39 - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05462236RecruitingPhase 2
Study drug AUM001 with immunotherapy or chemotherapy for metastatic colon cancer
This Phase 2 trial tests AUM001 (a targeted drug) combined with either pembrolizumab (an immunotherapy) or irinotecan (a chemotherapy) in people with metastatic colorectal cancer. It aims to shrink tumors and improve outcomes when standard treatments have already been tried.
Camperdown, New South WalesAges 18 years+ - NCT05462457Recruiting
Tests adding a targeted approach for breast cancer with many involved nodes
This trial studies a treatment plan for early breast cancer that involves at least three suspicious lymph nodes on the ultrasound/imaging. It looks at whether a targeted technique—done before surgery with chemotherapy—can improve or guide care when surgery will remove the lymph nodes.
EssenAges 18 years+ - NCT05462496RecruitingPhase 2
Pembrolizumab plus gut microbiome changes after pancreatic chemo
This Phase 2 study tests whether changing the gut microbiome (the gut’s helpful bacteria) and giving pembrolizumab after chemotherapy can improve outcomes for people with operable pancreatic cancer. It aims to see if this approach can boost the immune system after standard treatment and help reduce cancer returning.
New York, New YorkAges 19 years+ - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT05463263RecruitingPhase 1/Phase 2
Study drug for adults with relapsed or treatment-resistant lymphomas
This Phase 1/2 study tests dencatistat (STP938) to treat adults whose B-cell or T-cell lymphoma has come back or not responded to treatment. It looks at safety, the best dose, and whether it can shrink tumors or improve disease control when standard options have not helped.
Denver, ColoradoAges 18 years+ - NCT05463757Recruiting
Oral drugs for advanced or multiple basal cell skin cancer
This study registers people in the Netherlands who have certain types of basal cell skin cancer and take an oral hedgehog-blocking medicine. It may help doctors understand how well these tablets work and how patients do in real life.
Nijmegen, GelderlandAges Any age - NCT05463913RecruitingPhase 4
Scan and spot lung nodules with special PET/CT
This trial tests a newer PET/CT scan method to detect uncertain (indeterminate) lung nodules more accurately before biopsy or surgery. If you have a small lung nodule that doctors are still unsure about, this could help improve how nodules are found and assessed.
GroningenAges 18–100 - NCT05464719RecruitingPhase 2
Loncastuximab for lymphoma patients in partial remission after CAR T
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
Houston, TexasAges 18 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT05464992Recruiting
PET/MRI scan study using a special brain MRI technique
This trial studies whether a special type of MRI during a PET/MRI scan (called CEST) can help doctors better evaluate brain tumors and tumor return after treatment. It may improve how well scans show where disease is before surgery or when tumors come back.
StrasbourgAges 18 years+ - NCT05465161Recruiting
Marker used during solid organ surgery and transplant
This study uses a small “fiducial marker” (a reference point) during surgery on solid organs or during solid-organ transplant. It’s meant to help guide or track surgical planning, and could make certain procedures more precise.
Montreal, QuebecAges 18 years+ - NCT05465031RecruitingPhase 4
Testing heart-protection medicine during breast cancer treatment
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
Opole, Opole VoivodeshipAges 18 years+ - NCT05465954RecruitingPhase 2
Testing efinetakin and pembrolizumab for recurrent glioblastoma
This Phase 2 trial studies efinetakin alfa plus pembrolizumab for adults with recurrent glioblastoma (a fast-growing brain tumor). It aims to shrink or control the tumor and help patients live longer and better after standard treatments like surgery, radiation, and temozolomide.
Rochester, MinnesotaAges 18 years+ - NCT05466565Recruiting
Peginterferon antiviral treatment after liver cancer surgery
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
Changsha, HunanAges 18–65 - NCT05466786Recruiting
Testing gene changes and DNA damage in HER2-low breast cancer
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
Guangzhou, GuangdongAges 18–70 - NCT05467189Recruiting
Testing anti-cancer drugs in people age 65 and older
This study looks at how anti-cancer (chemotherapy) drugs are used in adults age 65+ who have cancer. It may help doctors understand which treatments work best and are safest for older adults.
Jinan, ShandongAges 65–100 - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT05468008Recruiting
Study of endoscopic submucosal removal (ESD)
This trial is checking outcomes for adults who are scheduled to have a procedure called endoscopic submucosal dissection (ESD), done through an endoscope. If you’re already planned for ESD and have no reasons you can’t have endoscopy, you may be able to join.
Orlando, FloridaAges 18 years+ - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT05468359RecruitingPhase 1/Phase 2
Testing four medicines in children and teens with hard-to-treat tumors
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Germantown, TennesseeAges Up to 30 years - NCT05468034Recruiting
Exercise program for metastatic breast cancer using a phone
This trial studies how a supervised exercise program (with treadmill walking and phone tracking) affects people living with metastatic breast cancer. It may help by improving fitness and day-to-day ability, especially if you’re currently not meeting regular exercise goals.
New Haven, ConnecticutAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,669 recruiting oncology studies from the U.S. registry right now, out of 31,797 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.